Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 3/20 | 0.38 |
| ▸ | DRD4 | P21917 | 3/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4900416 | 0.83 | DRD2 (0.41) | HDAC2HDAC3HDAC1DRD2NR4A2 | |
| SCHEMBL3865465 | 0.81 | LTA4H (0.40) | EGLN1HDAC2NR4A2FFAR1TSHR | |
| SCHEMBL4894394 | 0.80 | KDM4E (0.50) | EGLN1HDAC2ALDH1A1FFAR1TSHR | |
| SCHEMBL3859168 | 0.78 | LTA4H (0.47) | EGLN1HDAC2NR4A2FFAR1 | |
| SCHEMBL21384120 | 0.73 | POLB (0.60) | KDM5BALDH1A1LMNATSHRRAB9A | |
| SCHEMBL4898926 | 0.72 | KMT2A (0.40) | EGLN1ALDH1A1DRD2TSHRRAB9A | |
| SCHEMBL3164878 | 0.69 | PTGDR2 (0.53) | HDAC1RAB9A | |
| SCHEMBL15675117 | 0.68 | PSMB1 (0.57) | ALDH1A1LMNATSHRRAB9A | |
| SCHEMBL10059388 | 0.66 | KDM4E (0.49) | EGLN1HDAC2ALDH1A1RAB9ASRC | |
| SCHEMBL5439645 | 0.66 | DRD2 (0.49) | ALDH1A1DRD2DRD4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314087-B2 | Nitrogen-containing heterocyclyl ketones and methods of use | AMGEN INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20080280917-A1 | Nitrogen-Containing heterocyclyl ketones and methods of use | AMGEN INC. (US) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280917-A1 | Nitrogen-Containing heterocyclyl ketones and methods of use | HGF, HGFAC, MET | EGLN1 185/4885HDAC2 2491/4885HDAC3 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.